Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8655MR)

This product GTTS-WQ8655MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8655MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1102MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ1305MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ13841MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ8163MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ6006MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ9759MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ925MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ14849MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW